Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Emerging medical and engineering strategies for the prevention of long-term indwelling catheter blockage.

Milo S, Nzakizwanayo J, Hathaway HJ, Jones BV, Jenkins ATA.

Proc Inst Mech Eng H. 2018 May 1:954411918776691. doi: 10.1177/0954411918776691. [Epub ahead of print]

PMID:
29807465
2.

Development of an Infection-Responsive Fluorescent Sensor for the Early Detection of Urinary Catheter Blockage.

Milo S, Acosta FB, Hathaway HJ, Wallace LA, Thet NT, Jenkins ATA.

ACS Sens. 2018 Mar 23;3(3):612-617. doi: 10.1021/acssensors.7b00861. Epub 2018 Feb 14.

PMID:
29443508
3.

Innate Sex Bias of Staphylococcus aureus Skin Infection Is Driven by α-Hemolysin.

Castleman MJ, Pokhrel S, Triplett KD, Kusewitt DF, Elmore BO, Joyner JA, Femling JK, Sharma G, Hathaway HJ, Prossnitz ER, Hall PR.

J Immunol. 2018 Jan 15;200(2):657-668. doi: 10.4049/jimmunol.1700810. Epub 2017 Dec 8.

PMID:
29222165
4.

The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice.

Peretti AS, Dominguez D, Grimes MM, Hathaway HJ, Prossnitz ER, Rivera MR, Wandinger-Ness A, Kusewitt DF, Hudson LG.

Am J Pathol. 2018 Feb;188(2):515-524. doi: 10.1016/j.ajpath.2017.10.018. Epub 2017 Nov 21.

PMID:
29169987
5.

Cold-inducible RNA binding protein in mouse mammary gland development.

Lujan DA, Garcia S, Vanderhoof J, Sifuentes J, Brandt Y, Wu Y, Guo X, Mitchell T, Howard T, Hathaway HJ, Hartley RS.

Tissue Cell. 2016 Dec;48(6):577-587. doi: 10.1016/j.tice.2016.10.004. Epub 2016 Nov 5.

PMID:
27837912
6.

Study into the kinetic properties and surface attachment of a thermostable adenylate kinase.

Hathaway HJ, Sutton JM, Jenkins AT.

Biochem Biophys Rep. 2015 May;1:1-7.

7.

What have we learned about GPER function in physiology and disease from knockout mice?

Prossnitz ER, Hathaway HJ.

J Steroid Biochem Mol Biol. 2015 Sep;153:114-26. doi: 10.1016/j.jsbmb.2015.06.014. Epub 2015 Jul 16. Review.

8.

Magnetic relaxometry as applied to sensitive cancer detection and localization.

De Haro LP, Karaulanov T, Vreeland EC, Anderson B, Hathaway HJ, Huber DL, Matlashov AN, Nettles CP, Price AD, Monson TC, Flynn ER.

Biomed Tech (Berl). 2015 Oct;60(5):445-55. doi: 10.1515/bmt-2015-0053.

9.

GPER-targeted, 99mTc-labeled, nonsteroidal ligands demonstrate selective tumor imaging and in vivo estrogen binding.

Nayak TK, Ramesh C, Hathaway HJ, Norenberg JP, Arterburn JB, Prossnitz ER.

Mol Cancer Res. 2014 Nov;12(11):1635-43. doi: 10.1158/1541-7786.MCR-14-0289. Epub 2014 Jul 16.

10.

G protein-coupled estrogen receptor regulates mammary tumorigenesis and metastasis.

Marjon NA, Hu C, Hathaway HJ, Prossnitz ER.

Mol Cancer Res. 2014 Nov;12(11):1644-1654. doi: 10.1158/1541-7786.MCR-14-0128-T. Epub 2014 Jul 16.

11.

GPER mediates estrogen-induced signaling and proliferation in human breast epithelial cells and normal and malignant breast.

Scaling AL, Prossnitz ER, Hathaway HJ.

Horm Cancer. 2014 Jun;5(3):146-160. doi: 10.1007/s12672-014-0174-1. Epub 2014 Apr 10.

12.

Introduction of D-phenylalanine enhanced the receptor binding affinities of gonadotropin-releasing hormone peptides.

Lu J, Hathaway HJ, Royce ME, Prossnitz ER, Miao Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):725-30. doi: 10.1016/j.bmcl.2013.12.120. Epub 2014 Jan 6.

13.

G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth.

Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, Hathaway HJ, Prossnitz ER.

Obstet Gynecol Int. 2013;2013:472720. doi: 10.1155/2013/472720. Epub 2013 Nov 27.

14.

GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state.

Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, Prossnitz ER.

Endocrinology. 2013 Nov;154(11):4136-45. doi: 10.1210/en.2013-1357. Epub 2013 Aug 22.

15.

Development of antibody-tagged nanoparticles for detection of transplant rejection using biomagnetic sensors.

Butler KS, Lovato DM, Adolphi NL, Belfon R, Fegan DL, Monson TC, Hathaway HJ, Huber DL, Tessier TE, Bryant HC, Flynn ER, Larson RS.

Cell Transplant. 2013;22(10):1943-54. doi: 10.3727/096368912X657963. Epub 2012 Oct 12.

PMID:
23069078
16.

Imaging of Her2-targeted magnetic nanoparticles for breast cancer detection: comparison of SQUID-detected magnetic relaxometry and MRI.

Adolphi NL, Butler KS, Lovato DM, Tessier TE, Trujillo JE, Hathaway HJ, Fegan DL, Monson TC, Stevens TE, Huber DL, Ramu J, Milne ML, Altobelli SA, Bryant HC, Larson RS, Flynn ER.

Contrast Media Mol Imaging. 2012 May-Jun;7(3):308-19. doi: 10.1002/cmmi.499.

17.

Microenvironmental control of the breast cancer cell cycle.

Guo X, Wu Y, Hathaway HJ, Hartley RS.

Anat Rec (Hoboken). 2012 Apr;295(4):553-62. doi: 10.1002/ar.22417. Epub 2012 Jan 24. Review.

18.

Deletion of G protein-coupled estrogen receptor increases endothelial vasoconstriction.

Meyer MR, Amann K, Field AS, Hu C, Hathaway HJ, Kanagy NL, Walker MK, Barton M, Prossnitz ER.

Hypertension. 2012 Feb;59(2):507-12. doi: 10.1161/HYPERTENSIONAHA.111.184606. Epub 2011 Dec 27.

19.

Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors.

Hathaway HJ, Butler KS, Adolphi NL, Lovato DM, Belfon R, Fegan D, Monson TC, Trujillo JE, Tessier TE, Bryant HC, Huber DL, Larson RS, Flynn ER.

Breast Cancer Res. 2011 Nov 3;13(5):R108. doi: 10.1186/bcr3050.

20.

Identification of a GPER/GPR30 antagonist with improved estrogen receptor counterselectivity.

Dennis MK, Field AS, Burai R, Ramesh C, Petrie WK, Bologa CG, Oprea TI, Yamaguchi Y, Hayashi S, Sklar LA, Hathaway HJ, Arterburn JB, Prossnitz ER.

J Steroid Biochem Mol Biol. 2011 Nov;127(3-5):358-66. doi: 10.1016/j.jsbmb.2011.07.002. Epub 2011 Jul 14.

21.

Characterization of single-core magnetite nanoparticles for magnetic imaging by SQUID relaxometry.

Adolphi NL, Huber DL, Bryant HC, Monson TC, Fegan DL, Lim J, Trujillo JE, Tessier TE, Lovato DM, Butler KS, Provencio PP, Hathaway HJ, Majetich SA, Larson RS, Flynn ER.

Phys Med Biol. 2010 Oct 7;55(19):5985-6003. doi: 10.1088/0031-9155/55/19/023. Epub 2010 Sep 21.

22.

Three-dimensional collagen represses cyclin E1 via β1 integrin in invasive breast cancer cells.

Wu Y, Guo X, Brandt Y, Hathaway HJ, Hartley RS.

Breast Cancer Res Treat. 2011 Jun;127(2):397-406. doi: 10.1007/s10549-010-1013-x. Epub 2010 Jul 4.

23.

Influence of charge on cell permeability and tumor imaging of GPR30-targeted 111in-labeled nonsteroidal imaging agents.

Nayak TK, Dennis MK, Ramesh C, Burai R, Atcher RW, Sklar LA, Norenberg JP, Hathaway HJ, Arterburn JB, Prossnitz ER.

ACS Chem Biol. 2010 Jul 16;5(7):681-90. doi: 10.1021/cb1000636.

24.

Characterization of magnetite nanoparticles for SQUID-relaxometry and magnetic needle biopsy.

Adolphi NL, Huber DL, Jaetao JE, Bryant HC, Lovato DM, Fegan DL, Venturini EL, Monson TC, Tessier TE, Hathaway HJ, Bergemann C, Larson RS, Flynn ER.

J Magn Magn Mater. 2009 May 1;321(10):1459-1464.

25.

Synthesis and characterization of iodinated tetrahydroquinolines targeting the G protein-coupled estrogen receptor GPR30.

Ramesh C, Nayak TK, Burai R, Dennis MK, Hathaway HJ, Sklar LA, Prossnitz ER, Arterburn JB.

J Med Chem. 2010 Feb 11;53(3):1004-14. doi: 10.1021/jm9011802.

26.

Enhanced leukemia cell detection using a novel magnetic needle and nanoparticles.

Jaetao JE, Butler KS, Adolphi NL, Lovato DM, Bryant HC, Rabinowitz I, Winter SS, Tessier TE, Hathaway HJ, Bergemann C, Flynn ER, Larson RS.

Cancer Res. 2009 Nov 1;69(21):8310-6. doi: 10.1158/0008-5472.CAN-09-1083. Epub 2009 Oct 6.

27.

GPR30 predicts poor survival for ovarian cancer.

Smith HO, Arias-Pulido H, Kuo DY, Howard T, Qualls CR, Lee SJ, Verschraegen CF, Hathaway HJ, Joste NE, Prossnitz ER.

Gynecol Oncol. 2009 Sep;114(3):465-71. doi: 10.1016/j.ygyno.2009.05.015. Epub 2009 Jun 6.

28.

In vivo effects of a GPR30 antagonist.

Dennis MK, Burai R, Ramesh C, Petrie WK, Alcon SN, Nayak TK, Bologa CG, Leitao A, Brailoiu E, Deliu E, Dun NJ, Sklar LA, Hathaway HJ, Arterburn JB, Oprea TI, Prossnitz ER.

Nat Chem Biol. 2009 Jun;5(6):421-7. doi: 10.1038/nchembio.168.

29.

Preclinical development of a neutral, estrogen receptor-targeted, tridentate 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative for imaging of breast and endometrial cancers.

Nayak TK, Hathaway HJ, Ramesh C, Arterburn JB, Dai D, Sklar LA, Norenberg JP, Prossnitz ER.

J Nucl Med. 2008 Jun;49(6):978-86. doi: 10.2967/jnumed.107.048546. Epub 2008 May 15.

30.

Estrogen signaling through the transmembrane G protein-coupled receptor GPR30.

Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ.

Annu Rev Physiol. 2008;70:165-90. doi: 10.1146/annurev.physiol.70.113006.100518. Review.

PMID:
18271749
31.
32.

Mutational analysis of the cytoplasmic domain of beta1,4-galactosyltransferase I: influence of phosphorylation on cell surface expression.

Hathaway HJ, Evans SC, Dubois DH, Foote CI, Elder BH, Shur BD.

J Cell Sci. 2003 Nov 1;116(Pt 21):4319-30. Epub 2003 Sep 9.

34.
36.

Purification and characterization of avian beta 1,4 galactosyltransferase: comparison with the mammalian enzyme.

Hathaway HJ, Runyan RB, Khounlo S, Shur BD.

Glycobiology. 1991 Mar;1(2):211-21.

PMID:
1823164
37.

Analysis of cell surface galactosyltransferase activity during mouse trophectodermal differentiation.

Hathaway HJ, Romagnano LC, Babiarz BS.

Dev Biol. 1989 Aug;134(2):351-61.

PMID:
2501126
38.

Novel cell surface receptors during mammalian fertilization and development.

Hathaway HJ, Shur BD.

Bioessays. 1988 Nov;9(5):153-8. Review. No abstract available.

PMID:
3149196
39.

Hormonal control of the expression of antibody-defined lactosaminoglycans in the mouse uterus.

Babiarz BS, Hathaway HJ.

Biol Reprod. 1988 Oct;39(3):699-706.

PMID:
3196800
41.

The developmental pathology of maternally derived Thp fetuses.

Babiarz BS, Donovan MJ, Hathaway HJ.

Teratology. 1988 Apr;37(4):353-64.

PMID:
3293259
42.

Supplemental Content

Loading ...
Support Center